Table 3.

Multivariable Cox-regression model analysis of PFS.

Independent predictive factor	Before PSM			After PSM
	HR	95% CI	p-value	HR	95% CI	p-value
Pembrolizumab vs. Sintilimab	0.815	0.482–1.379	0.446	0.859	0.466–1.583	0.627
Male vs. Female	0.696	0.362–1.338	0.277	0.862	0.368–3.871	0.733
Age (>60 yr vs. ≤60 yr)	0.556	0.350–0.884	0.695	0.721	0.390–1.331	0.295
PS score (≥2 vs. 0–1)	0.576	0.174–1.909	0.367	1.540	0.796–2.978	0.200
Histological type (Squamous carcinoma vs. Adenocarcinoma)	1.016	0.597–1.728	0.954	1.074	0.494–2.336	0.857
TNM stage (IV vs. III)	0.880	0.465–1.665	0.695	1.206	0.376–3.871	0.753
Bain metastases (Yes vs. No)	1.168	0.897–3.171	0.105	1.816	0.859–3.839	1.118
Lines (First line vs. Second or more line)	2.403	1.464–3.945	0.001	2.865	1.438–5.704	0.03
Comorbidity (Yes vs. No)	1.588	0.995–2.534	0.052	1.103	0.585–2.336	0.761
Smoking status (No vs. Yes)	0.859	0.476–1.549	0.612	0.699	0.316–1.546	0.376
Regimen (Without radiotherapy vs. With radiotherapy)	0.492	0.291–0.799	0.005	0.314	0.149–0.662	0.002